HHS plans to cut 10,000 jobs, close offices, and merge agencies
Chief Healthcare Executive March 27, 2025
Sanofi Expands Immunology Prospects, Acquiring Novel Bispecific Drug in $600M Deal
MedCity News March 20, 2025
Sanofi is building on its immunology ambitions by acquiring an early clinical Dren Bio drug candidate that offers a potential first-in-class approach to autoimmune disorders such as lupus. It’s the latest acquisition in what has become an active space for dealmaking.
Bispecific antibodies first reached patients as cancer treatments, but a growing number of companies are working to expand these therapies to autoimmune diseases. Sanofi is adding a new contender, agreeing to pay $600 million for a bispecific drug with an approach that could be first in class.
The sum announced Thursday is an upfront payment for Dren Bio’s drug candidate, DR-0201. The privately held biotech, which is based in Foster City, California, could receive up to $1.3 billion more...
Today's Sponsors
Today's Sponsor